we reach people

The most advanced drugs are of no use if patients don’t
have access to them. Biologics are a case in point.

no matter where

There is an urgent need to improve access to biologics
in the Canadian population, to deliver international
standard of care and optimize health outcomes.1

Viatris has successfully introduced
biosimilars in 76 countries with the first
one approved in Canada in 2018. What
others hope to do in the future, Viatris is
delivering today.

it’s what we do

Viatris Inc., is a new kind of healthcare company, empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind GLOBAL HEALTHCARE GATEWAY®.

Formed in November 2020, through the combination of Mylan and Pfizer's Upjohn business, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, a growing portfolio of biosimilars and a variety of over-the-counter consumer products.

Viatris AdvocateTM Patient Support Programs

Viatris believes in extending support services to patients at every stage of their journey regardless of their reimbursement profile. Viatris AdvocateTM programs are in place to help healthcare providers and patients navigate their personal reimbursement landscape, provide financial assistance when needed, and a suite of other services tailored to the product the patient has been prescribed.

Reference:

  1. LeBlanc CM, Lang B, Bencivenga A, et al. Access to biologic therapies in Canada for children with juvenile idiopathic arthritis. J Rheumatol. 2012;39(9):1875-9.